Paper Review Records
All Paper Review Records
13 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
AAV-mediated genome targeting of the GLA cDNA in newborn and juvenile Gla KO mice achieves long-term correction of Fabry disease
Himanshi Saxena; Giulia Romano; Rossana Domenis; Jessica Biasizzo; Martina Ferro; Dania Ferino; Antonio Vicidomini; Andrea Colliva; Alessandra Iaconcig; Giulia Bortolussi; Lorena Zentilin; Andrea Dardis; Andrés F. MuroShow moreShow less
1. International Centre for Genetic Engineering and Biotechnology, Padriciano, 99, 34149 Trieste, Italy; 2. Institute of Clinical Pathology, Department of Laboratory Medicine, University Hospital of Udine, P. Le Santa Maria Della Misericordia 15, 33100 Udine, Italy; 3. Regional Coordinator Centre for Rare Diseases, University Hospital of Udine, P. Le Santa Maria Della Misericordia 15, 33100 Udine, ItalyShow moreShow less
Inhibition of immune response reduces pathology in dorsal root ganglia and peripheral nerves in cynomolgus macaques following AAV gene therapy
Branka Grubor; Kate L. Henry; Su Jing Chan; Mark Sheehan; Anumeha Shah; Alex Pellerin; Judy Bai; Prasad Nadella; Santhosh Bommegowda; Patrick Cullen; Eric Tien; Vivian Chen; Nicholas P. van der Munnik; Stephanie White-Hunt; Edward D. Plowey; Stefan Hamann; Amanda J. Guise; Shanqin Xu; Melissa Kirkland; Jessica Doherty; Eugenia Lyashenko; Guruharsha Bhat; Kelly Glajch; Shih-Ching Lo; Davide Gianni; Pete Clarner; Jake Gagnon; Jenhwa Chu; Kalyani Nambiar; Mukesh Lulla; Fengmei Zheng; Asmerom Weldeab; Dan Bartlett; Amos Gutnick; Taylor Reynolds; Kan Zhu; Dann Huh; Thomas M. Carlile; James Fikes; Patrick Trapa; Junghae Suh; Dale Morris; Linda BurklyShow moreShow less
Biogen, Cambridge, MA 02142, USA; Charles River Laboratories, Durham, NC 27703, USAShow moreShow less
Leveraging the active conformation of LFA-1 as a potential target for hematological malignancies
Abhishek Puthenveetil; Guy Biber; Batel Sabag; Meirav Kedmi; Avigdor Abraham; Noah Joseph; Mira Barda-SaadShow moreShow less
The Mina and Everard Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan 5290002, Israel; The Chaim Sheba Medical Center, Tel-Hashomer, Ramat-Gan, Israel; Sackler School of Medicine, Tel- Aviv University, Tel-Aviv, IsraelShow moreShow less
AAV-PHP.eB achieves superior neuronal transduction over AAV9 in pigtail macaques following intracerebroventricular administration
Michal G. Fortuna; Lyle H. Nyberg; Naz Taskin; Avery Hunker; Natalie Weed; Kathryn Gudsnuk; Melissa Berg; Boaz P. Levi; Ed Lein; Jonathan T. TingShow moreShow less
Allen Institute for Brain Science, Seattle, WA, USA; Washington National Primate Research Center, Seattle, WA, USA; Department of Neurological Surgery, University of Washington, Seattle, WA, USA; Department of Neurobiology & Biophysics, University of Washington, Seattle, WA, USAShow moreShow less
Nonclinical toxicity study duration in AAV gene therapy development: Evidence from industry survey supports adequacy of short-term assessments
Basel T. Assaf; David Edwards; Shawn Jay Berens; Brian Lauritzen; Christelle Pierrot; Francis Fonyuy Tukov; Cristina Bertinetti-Lapatki; Manuela Braun; Kai Schaefer; Jessica L. LynchShow moreShow less
Sanofi, Cambridge, MA 02141, USA; UCB Pharma, Slough, UK; Eli Lilly and Company, Indianapolis, IN 46285, USA; Novo Nordisk A/S, Maaloev, Denmark; Astellas Pharma B.V., Leiden, the Netherlands; Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936, USA; Roche Innovation Center, 4070 Basel, Switzerland; Bayer AG, 13342 Berlin, Germany; AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany; Johnson & Johnson Innovative Medicine, Spring House, PA 19477, USAShow moreShow less
Gene therapy supports long-term reconstitution of patient hematopoietic stem cells in deficiency of adenosine deaminase 2
Chiara Rigamonti; Dimitri Bulté; Federica Barzaghi; Cristina Mesa-Nuñez; Luca Basso-Ricci; Emanuela Pettinato; Camilla Visconti; Sara Degl’Innocenti; Francesco Gazzo; Fabrizio Benedicenti; Sergio Arévalo; Pamela Quaranta; Francesca Sanvito; Roberta Caorsi; Francesca Schena; Michela Lupia; Silvia Federici; Antonella Insalaco; Fabrizio De Benedetti; Serena Scala; Maurizio Miano; Francesca Conti; Maria Pia Cicalese; Eugenio Montini; Marco Gattorno; Carlo Dufour; Alessandro Aiuti; Alessandra MortellaroShow moreShow less
San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy; Vita-Salute San Raffaele University, 20132 Milan, Italy; Pediatric Immunohematology and Bone Marrow Transplantation Unit, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy; GLP Test Facility, San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy; Pathology Unit, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy; Department of Electronics, Information and Bioengineering, Politecnico di Milano, 20133 Milan, Italy; UOC Rheumatology and Autoinflammatory Diseases, IRCCS Istituto Giannina Gaslini, 16147 Genoa, Italy; Hematology Unit, IRCCS Istituto Giannina Gaslini, 16147 Genoa, Italy; Division of Rheumatology, Bambino Gesù Children’s Hospital, ERN-RITA Center, IRCCS, 00165 Rome, Italy; Pediatric Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy; Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, 40126 Bologna, ItalyShow moreShow less
FAQ
How long does Molecular Therapy Methods & Clinical Development take to review a manuscript?
As of 2026-11-19, CrushSCI has 13 complete review records for Molecular Therapy Methods & Clinical Development. The fastest paper went from submission to acceptance in 42 days (Gene therapy supports long-term reconstitution of patient hematopoietic stem cells in deficiency of adenosine deaminase 2, received 2025-09-16, accepted 2025-10-28); the slowest took 463 days. The average is 166 days and the median is 147 days.
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
